Medical Microbiology and Immunology

, Volume 196, Issue 4, pp 203–212

The threat of avian influenza A (H5N1). Part III: antiviral therapy



Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 as well as treatment options are discussed. The third part discusses therapeutic options. Neuraminidase (NA) inhibitors are the most promising agents despite uncertainty about efficacy. Dosage increase, prolonged treatment or combination therapies may increase treatment efficacy and/or inhibit resistance formation. Immune system dysregulation contributes to H5N1 disease. Although current evidence does not support the use of anti-inflammatory drugs beneficial effects cannot be excluded at later disease stages.


  1. 1.
    Webster RG, Govorkova EA (2006) H5N1 influenza-continuing evolution and spread. N Engl J Med 355:2174–7PubMedCrossRefGoogle Scholar
  2. 2.
    Cinatl J Jr, Michaelis M, Doerr HW (2007) The threat of avian influenza A (H5N1)-part I: epidemiologic concerns and virulence determinants. Med Microbiol Immunol (in press)Google Scholar
  3. 3.
    Schünemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, Farrar J, Tran TH, Ozbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist GE, Croisier A, Nagjdaliyev A, Roth C, Thomson G, Zucker H, Oxman AD; WHO rapid advice guideline panel on avian influenza (2007)WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7:21–31PubMedCrossRefGoogle Scholar
  4. 4.
    The writing committee of the World Health Organization (WHO) consultation on human influenza A/H5 (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374–1385CrossRefGoogle Scholar
  5. 5.
    Cinatl J Jr, Michaelis M, Doerr HW (2007) The threat of avian influenza A (H5N1)-part II: Clues to the pathology. Med Microbiol Immunol (in press)Google Scholar
  6. 6.
    de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203–1207PubMedCrossRefGoogle Scholar
  7. 7.
    Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, Zhang J, Yuen KY, Webster RG, Peiris JS, Guan Y, Chen H (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193:1626–1629PubMedCrossRefGoogle Scholar
  8. 8.
    de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667–2672PubMedCrossRefGoogle Scholar
  9. 9.
    Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144:862–863PubMedCrossRefGoogle Scholar
  10. 10.
    Tsunoda A, Maassab HF, Cochran KW, Eveland WC (1965) Antiviral activity of alpha-methyl-1-adamantanemethylamine hydrochloride. Antimicrob Agents Chemother 5:553–560PubMedGoogle Scholar
  11. 11.
    Hayden FG (2006) Antiviral for influenza: historical perspectives and lessons learned. Antiviral Res 71:372–378PubMedCrossRefGoogle Scholar
  12. 12.
    Hay AJ (1992) The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel proteins. Semin Virol 3:21–30Google Scholar
  13. 13.
    Chizhmakov IV, Geraghty FM, Ogden DC, Hayhurst A, Antoniou M, Hay AJ (1996) Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J Physiol 494:329–336PubMedGoogle Scholar
  14. 14.
    Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4:3021–3024PubMedGoogle Scholar
  15. 15.
    Ruigrok RW, Hirst EM, Hay AJ (1991) The specific inhibition of influenza A virus maturation by amantadine: an electron microscopic examination. J Gen Virol 72:191–194PubMedGoogle Scholar
  16. 16.
    Couch RB (2000) Prevention and treatment of influenza. N Engl J Med 343:1778–1787PubMedCrossRefGoogle Scholar
  17. 17.
    Monto AS (2006) Vaccines and antviral drugs in pandemic preparedness. Emerg Infect Dis 12:55–60PubMedGoogle Scholar
  18. 18.
    Monto AS, Gunn RA, Bandyk MG, King CL (1979) Prevention of Russian influenza by amantadine. JAMA 241:1003–1007PubMedCrossRefGoogle Scholar
  19. 19.
    Monto AS (2003) The role of antivirals in the control of influenza. Vaccine 21:1796–1800PubMedCrossRefGoogle Scholar
  20. 20.
    Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W (1989) Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321:1696–1702PubMedCrossRefGoogle Scholar
  21. 21.
    Abed Y, Goyette N, Boivin G (2005) Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 49:556–559PubMedCrossRefGoogle Scholar
  22. 22.
    Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:119–130PubMedGoogle Scholar
  23. 23.
    Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y (2003) High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188:57–61PubMedCrossRefGoogle Scholar
  24. 24.
    Boivin G, Goyette N, Bernatchez H (2002) Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 34:E23–25PubMedCrossRefGoogle Scholar
  25. 25.
    Saito R, Sakai T, Sato I, Sano Y, Oshitani H, Sato M, Suzuki H (2003) Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 41:2164–2165PubMedCrossRefGoogle Scholar
  26. 26.
    Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175–1181PubMedCrossRefGoogle Scholar
  27. 27.
    Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–984PubMedCrossRefGoogle Scholar
  28. 28.
    Ilyushina NA, Govorkova EA, Russel CJ, Hoffmann E, Webster RG (2007) Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. J Gen Virol 88:1266–1274PubMedCrossRefGoogle Scholar
  29. 29.
    Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris JS (2004) Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209–213PubMedCrossRefGoogle Scholar
  30. 30.
    Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG (2007) Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73:228–231PubMedCrossRefGoogle Scholar
  31. 31.
    Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–1373PubMedCrossRefGoogle Scholar
  32. 32.
    Palese P, Tobita K, Ueda M, Compans RW (1974) Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397–410PubMedCrossRefGoogle Scholar
  33. 33.
    Palese P, Compans RW (1976) Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33:159–163PubMedCrossRefGoogle Scholar
  34. 34.
    Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665–12667PubMedCrossRefGoogle Scholar
  35. 35.
    Ohuchi M, Asaoka N, Sakai T, Ohuchi R (2006) Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 8:1287–1293PubMedCrossRefGoogle Scholar
  36. 36.
    Boivin G, Goyette N (2002) Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 54:143–147PubMedCrossRefGoogle Scholar
  37. 37.
    Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, Hayden FG (2003) Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 41:742–750PubMedCrossRefGoogle Scholar
  38. 38.
    Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnenb AM, Hirst HM, Keene O, Wightman K (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 influenza study group. N Engl J Med 337:874–880PubMedCrossRefGoogle Scholar
  39. 39.
    Makela MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40:42–48PubMedCrossRefGoogle Scholar
  40. 40.
    Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase inhibitor flu treatment investigator group. Lancet 355:1845–1850PubMedCrossRefGoogle Scholar
  41. 41.
    Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group. JAMA 283:1016–1024PubMedCrossRefGoogle Scholar
  42. 42.
    Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P; IMPACT Study Group (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51:123–129PubMedCrossRefGoogle Scholar
  43. 43.
    Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19:410–417PubMedCrossRefGoogle Scholar
  44. 44.
    Lalezari J, Campion K, Keene O, Silagy C (2001) Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 161:212–217PubMedCrossRefGoogle Scholar
  45. 45.
    Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133PubMedCrossRefGoogle Scholar
  46. 46.
    Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667–1672PubMedCrossRefGoogle Scholar
  47. 47.
    Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ; Zanamivir Family Study Group (2000) Inhaled zanamivir for the prevention of influenza in families. Zanamivir family study group. N Engl J Med 343:1282–1289PubMedCrossRefGoogle Scholar
  48. 48.
    Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189:440–449PubMedCrossRefGoogle Scholar
  49. 49.
    Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS; Oseltamivir post exposure prophylaxis investigator group (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285:748–754PubMedCrossRefGoogle Scholar
  50. 50.
    Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C (2002) Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 186:1582–1588PubMedCrossRefGoogle Scholar
  51. 51.
    Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1341:1336–1343CrossRefGoogle Scholar
  52. 52.
    Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 282:31–35PubMedCrossRefGoogle Scholar
  53. 53.
    Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG (2001) Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45:2723–2732PubMedCrossRefGoogle Scholar
  54. 54.
    Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG (2001) The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101–115CrossRefGoogle Scholar
  55. 55.
    Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48:4855–4863PubMedCrossRefGoogle Scholar
  56. 56.
    Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007 Feb 12; (Epub ahead of print)Google Scholar
  57. 57.
    Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S,Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A, Dowell SF (2005) Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11:201–209PubMedGoogle Scholar
  58. 58.
    Ferraris O, Kessler N, Lina B (2005) Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 68:43–48PubMedCrossRefGoogle Scholar
  59. 59.
    Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G (2002) Characterization of 2 influenza A (H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 186:1074–1080PubMedCrossRefGoogle Scholar
  60. 60.
    Abed Y, Baz M, Boivin G (2006) Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971–976PubMedGoogle Scholar
  61. 61.
    Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55(Suppl 1):i5-i21PubMedCrossRefGoogle Scholar
  62. 62.
    Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765PubMedCrossRefGoogle Scholar
  63. 63.
    Normile D, Enserink M (2007) Avian influenza. With change in the seasons, bird flu returns. Science 315:448PubMedCrossRefGoogle Scholar
  64. 64.
    Oxford JS (2007) Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza 1:27–34CrossRefGoogle Scholar
  65. 65.
    Yen HL, Monto AS, Webster RG, Govorkova EA (2005) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192:665–672PubMedCrossRefGoogle Scholar
  66. 66.
    Sidwell RW, Bailey KW, Bemis PA, Wong MH, Eisenberg EJ, Huffman JH (1999) Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104. Antivir Chem Chemother 10:187–193PubMedGoogle Scholar
  67. 67.
    Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A (2000) The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64–0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 40:836–843PubMedCrossRefGoogle Scholar
  68. 68.
    Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587–593PubMedCrossRefGoogle Scholar
  69. 69.
    Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG (1999) Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 43:1616–1620PubMedGoogle Scholar
  70. 70.
    Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, Steigbigel R, Elliott M, Weiss HL, Hayden FG; NIAID Collaborative antiviral study group (2003) Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8:183–190PubMedGoogle Scholar
  71. 71.
    Cass LM, Efthymiopoulos C, Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36(Suppl 1):1–11PubMedCrossRefGoogle Scholar
  72. 72.
    Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 21–31CrossRefGoogle Scholar
  73. 73.
    Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of virazole: 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705–706PubMedCrossRefGoogle Scholar
  74. 74.
    Khare GP, Sidwell RW, Witkowski JT, Simon LN, Robins RK (1973) Suppression by 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice. Antimicrob Agents Chemother 3:517–522PubMedGoogle Scholar
  75. 75.
    Hong Z, Cameron CE (2002) Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 59:41–69PubMedGoogle Scholar
  76. 76.
    Gish RG (2006) Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 57:8–13PubMedCrossRefGoogle Scholar
  77. 77.
    Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM, Bernstein DI (1987) Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 31:1285–1287PubMedGoogle Scholar
  78. 78.
    Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, Johnson G, Van Dyke R, Groothuis JR, Arrobio J (1994) Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 125:129–135PubMedCrossRefGoogle Scholar
  79. 79.
    Hayden FG, Sable CA, Connor JD, Lane J (1996) Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir Ther 1:51–56PubMedGoogle Scholar
  80. 80.
    Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 68:10–17PubMedCrossRefGoogle Scholar
  81. 81.
    Smee DF, Wandersee MK, Wong MH, Bailey KW, Sidwell RW (2004) Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine. Antivir Chem Chemother 15:261–268PubMedGoogle Scholar
  82. 82.
    Wu JZ, Walker H, Lau JY, Hong Z (2003) Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 47:426–431PubMedCrossRefGoogle Scholar
  83. 83.
    Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, Pham TS, Vo CD, Le TQ, Ngo TT, Dao BK, Le PP, Nguyen TT, Hoang TL, Cao VT, Le TG, Nguyen DT, Le HN, Nguyen KT, Le HS, Le VT, Christiane D, Tran TT, Menno de J, Schultsz C, Cheng P, Lim W, Horby P, Farrar J; World Health Organization international avian influenza investigative team (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350:1179–1188PubMedCrossRefGoogle Scholar
  84. 84.
    Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M, Simon HU (1997) Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 52:144–154PubMedCrossRefGoogle Scholar
  85. 85.
    Johnston SL (2005) Overview of virus-induced airway disease. Proc Am Thorac Soc 2:150–156PubMedCrossRefGoogle Scholar
  86. 86.
    Billiau A (2006) Anti-inflammatory properties of Type I interferons. Antiviral Res 71:108–116PubMedCrossRefGoogle Scholar
  87. 87.
    Seo SH, Hoffmann E, Webster RG (2002) Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 8:950–954PubMedCrossRefGoogle Scholar
  88. 88.
    Seo SH, Hoffmann E, Webster RG (2004) The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res 103:107–113PubMedCrossRefGoogle Scholar
  89. 89.
    Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY, Guan Y (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363:617–619PubMedCrossRefGoogle Scholar
  90. 90.
    Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162:3549–3558PubMedGoogle Scholar
  91. 91.
    Rainsford KD (2006) Influenza (“bird flu”), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology 14:2–9PubMedCrossRefGoogle Scholar
  92. 92.
    Huang RT, Dietsch E (1988) Anti-influenza viral activity of aspirin in cell culture. N Engl J Med 319:797PubMedGoogle Scholar
  93. 93.
    Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S (2007) Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-κB-inhibiting activity. Cell Microbiol (Epub ahead of print)Google Scholar
  94. 94.
    D’Acquisto F, Ianaro A (2006) From willow bark to peptides: the ever widening spectrum of NF-κB inhibitors. Curr Opin Pharmacol 6:387–392PubMedCrossRefGoogle Scholar
  95. 95.
    van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T (2006) H5N1 virus attachment to lower respiratory tract. Science 312:399PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Institute for Medical VirologyHospital of the Johann Wolfgang Goethe UniversityFrankfurt/MGermany

Personalised recommendations